Chargement en cours...
Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
Background: Pediatric multiple sclerosis (MS) is rare: only 1.5–5% of MS cases are diagnosed before 18 years of age, and data on disease-modifying therapies (DMTs) for pediatric MS are limited. The CONNECTED study assessed the long-term safety and efficacy of treatment with delayed-release dimethyl...
Enregistré dans:
| Publié dans: | Front Neurol |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7812971/ https://ncbi.nlm.nih.gov/pubmed/33473248 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2020.606418 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|